Molecular Response of e19a2 BCR-ABL1 Chronic Myeloid Leukemia With Double Philadelphia Chromosome to Dasatinib

J Clin Oncol. 2016 May 10;34(14):e130-3. doi: 10.1200/JCO.2013.51.1188. Epub 2014 Apr 21.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Dasatinib / therapeutic use*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
  • Philadelphia Chromosome*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Fusion Proteins, bcr-abl
  • Dasatinib